{"url_path":"/sec/fth/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225333-index.html","accession_number":"0001193125-26-225333","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225333-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":53,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nRule 10b5-1 Trading Plans\n\nDuring the fiscal quarter ended March 31, 2026, none of our officers or directors, as defined in Rule 16a-1(f), adopted, modified or terminated a \"Rule 10b5-1 trading arrangement\" or a \"non-Rule 10b5-1 trading arrangement,\" as those terms are defined in Item 408 of Regulation S-K."}